To Develop and Validate RP-HPLC Analytical Technique for the Solid Dosage Forms of Dapagliflozin and Metformin Hydrochloride

 

Ragini Ghotale, Sameep Sonvane*, Kranti Satpute, Mahesh Birajdar, Balaji Shetkar,

Gopal Lohiya, Prakash Shivnechari

Dayanand Education Society’s, Dayanand College of Pharmacy, Latur, Maharashtra, India.

*Corresponding Author E-mail: sameepsonvane@rediffmail.com

 

ABSTRACT:

A straightforward, precise, and high-performance reverse phase liquid chromatography technique has been created for the simultaneous measurement of Metformin hydrochloride and Dapagliflozin in solid dose form. The HPLC model was used to make the determination: For chromatographic separation, an Agilent 1260 Infinity II with an Agilent 5 TC-C18 (2) 250 × 4.6mm column was utilized. PDA detector was applied. The mobile phase's flow rate was increased to 1 milliliter per minute and contained 0.02% triethylamine: acetonitrile (50:50 v/v). A 236 nm wavelength and a 50 µl injection volume were chosen for the detection. The retention times for Dapagliflozin and metformin, when using the described approach, were determined to be 5.6 and 2.6 minutes, respectively. The linearity, accuracy, and precision of the procedure have all been confirmed. Dapagliflozin and Metformin's linearity were in between 30 and 70 μg/ml and 0.6 and 1.4 μg/ml, respectively. Metformin and Dapagliflozin were shown to have percentage recoveries of 101.88% and 99.35%, respectively. The analytical processes are deemed suitable for their intended purpose and meet the standards outlined in ICH Q2R2, as evidenced by the results of the validation parameters.

 

KEYWORDS: Metformin hydrochloride, Dapagliflozin, RP-HPLC, Validation, Robustness.

 

 


INTRODUCTION: 

The process of choosing a precise assay technique to determine a formulation's composition is known as analytical method development. The process of developing an analytical method is what establishes its suitability for usage in a laboratory setting. The ICH recommendations Q2 (R1) include procedures and acceptance criteria for the development of analytical methods, which must be utilized in GMP and GLP contexts1. The "process of establishing documented evidence" known as "method validation" offers a high degree of assurance that the equipment or product will satisfy the needs of the intended analytical applications2.

 

A validation analysis involves evaluating several aspects of a technique to ascertain whether, when used robotically, it could yield accurate and meaningful data 3-7. The validation test should contain standard test circumstances, such as product excipients, in order to precisely examine method parameters. As a result, a method validation analysis is product-specific8-12.

 

Metformin hydrochloride is to treat type 2 diabetes mellitus. It is a member of the biguanide medication class and acts by enhancing insulin sensitivity in adipose and muscle cells and reducing the liver's synthesis of glucose. This aids in lowering blood sugar. Metformin improves glucose absorption by cells by decreasing the liver's ability to produce glucose (gluconeogenesis) and raising insulin sensitivity13-17.

 

 

Figure No 1: Metformin HCl

In similar way, Dapagliflozin is to treat type 2 diabetes mellitus. It is a member of the group of medications called inhibitors of the sodium-glucose co-transporter 2 (SGLT2). It functions by preventing the kidneys' SGLT2 protein, which is in charge of reabsorption of glucose. Dapagliflozin lowers blood glucose levels by increasing the excretion of glucose in urine and inhibiting SGLT2 18-20.

 

 

Figure No 2: Dapagliflozin

 

The primary goal of this effort is to create and validate a Reverse Phase- High Performance Liquid Chromatography method that will allow the official guidelines to be followed in determining the solid dosage form of Dapagliflozin and Metformin21-25.

 

MATERIALS AND METHODS:

Analytical and Software:

Chromatography was performed on, an Agilent 1260 Infinity II with open lab CDS 2.7 as a software and Agilent 5 TC-C18 (2) 250 × 4.6mm column was utilized. PDA detector was applied. The mobile phase's flow rate was increased to 1 milliliter per minute and contained 0.02% triethylamine: acetonitrile (50:50 v/v). A 236nm wavelength and a 50µl injection volume were chosen for the detection.

 

Reagent and Chemicals:

HPLC grade solvent such as triethylamine and acetonitrile from Research Lab were used for this present work. Active pharmaceutical ingredients were procured from Smruthi Organics Limited, Solapur.

 

Preparation of Mobile Phase:

In order to prepare the mobile phase, 0.1ml of triethylamine was combined with 500ml of HPLC grade water. Acetonitrile were added in a 50:50 v/v ratio, and the mixture was well mixed. The mobile phase was then filtered using what's man filter paper no. 41 and degassed using sonication for approximately 10 minutes.

 

Chromatographic Condition:

Agilent 1260 Infinity II with an Agilent 5 TC-C18 (2) 250 × 4.6mm column was utilized for chromatographic resolution a detection of wavelength 236nm.Mobile phase used 0.02% Triethylamine: Acetonitrile (50:50) v/v. The elution was monitored by injecting the 50μl and the flow rate was adjusted to 1ml/min.

 

Preparation of Standard Solution:

Weigh out 250mg of Metformin hydrochloride and 5mg of Dapagliflozin precisely, and then transfer into a 100 ml different volumetric flask. To this added 50ml of diluent it is Sonicated for 10min and makeup the volume        up to (100ml) the mark. Filter the mixture using what’s man filter paper No. 41. Pipetted out 2ml of the previously prepared each solution and placed into a second 100ml volumetric flask. Added water to the volumetric flask until the indicated volume is reached(.

 

RESULT AND DISCUSSION:

Chromatographic Condition Optimization:

The impact of chromatographic factors such mobile phase ratio, mobile phase composition, and flow rate were examined in order to optimize chromatographic conditions. Chromatographic characteristics including tailing factor, capacity factor, and theoretical plate count were computed after the resultant chromatograms were recorded. Ultimately, a straightforward and economical technique was created by using 0.02% Triethylamine: Acetonitrile (50:50). Table No. 1 contains a list of ideal chromatographic conditions.

 

Table No 1: chromatographic conditions

Method Parameter

Optimized Value

Column

Agilent 5 TC-C18 (2) 250 × 4.6mm column

Particle size packing

5 μ

Stationary phase

5 TC-C18 (2)

Mobile Phase

0.02% Triethylamine: Acetonitrile (50:50) v/v

Detection Wavelength

236nm

Flow rate

1.0 ml/min

Sample size

50 μL

 

 

Figure No 3: Chromatogram of Metformin HCl and Dapagliflozin

 

Method Validation:

Linearity and Range:

The calibration curve was constructed by plotting concentrations versus peak areas, and the regression equations were calculated. The linear regression equation is Y = 239.73x+286.92.


 

Figure No 4: Calibration Curve for Metformin HCl

 

Figure No 5: Calibration Curve for Dapagliflozin

The results show that all the system suitability parameters meet the acceptance   criteria. The results show that the response is found to be linear. Correlation coefficient is more than 0.99 hence; the method is linear in the given tested range i.e. 30PPM-70PPM for Metformin Hydrochloride and 0.6PPM-1.4PPM for Dapagliflozin.

 

Accuracy:

The degree of agreement between True value and Found value is expressed by the accuracy of an analytical technique. The accuracy of the procedure is within acceptable bounds, according to the accuracy test findings. As Table No. 2 and 3 shows, the HPLC method is accurate in determining the assay of Metformin Hydrochloride and Dapagliflozin tablet since the mean recovery of these two drugs is 101.88% and 99.35%, respectively, and the percentage RSD of these two drugs is 0.531% and 0.871%, respectively.

 

Precision:

Six replicate injections of a sample injected. The results' percentage RSD (relative standard deviation, was computed). (table-4).


 

Table No 2: Data sheet for Accuracy (Metformin HCl)

% Level

Set

Amount Added (mg)

Amount Recovery (mg)

% Recovery

Mean

SD

% RSD

80%

1

204

209.305

102.6006

 

102.649

 

0.133

 

0.129

2

204.9

210.636

102.7995

3

206

211.2467

102.5469

100%

 

1

250

253.653

101.461

100.140

1.367

1.365

2

250

250.577

100.230

3

247

243.863

98.730

120%

 

 

1

302

310.946

102.962

102.864

0.104

0.101

2

308

316.856

102.875

3

308.8

317.305

102.754

 

Table No 3: Data sheet for Accuracy Dapagliflozin

% Level

Set

Amount Added (mg)

Amount Recovery (mg)

% Recovery

Mean

SD

%RSD

80%

 

1

4

4.044

101.116

100.453

0.582

0.580

2

3.9

3.900

100.022

3

4.1

4.109

100.222

100%

 

 

1

4.8

4.781

99.606

99.141

0.755

0.761

2

4.8

4.716

98.270

3

5

4.977

99.548

120%

1

5.8

5.642

97.287

98.458

1.183

1.201

2

5.8

5.779

99.653

3

6

5.906

98.434

 

Table No 4: Data sheet for Precision

Sample No.

Metformin Hydrochloride

Dapagliflozin

Sample Area

%Assay

Sample Area

% Assay

1.

11491.865

101.89

83.311

101.91

2.

11586.052

102.72

81.384

99.55

3.

11162.544

100.58

78.226

97.25

4.

11461.449

103.09

78.345

97.22

5.

11007.813

99.01

81.679

101.36

6.

11727.338

103.98

79.753

97.56

Average

-

101.877

-

98.590

SD

-

2.030

-

1.825

%RSD

-

1.992

-

1.851

The % RSD of the method precision for Metformin Hydrochloride is 1.992% and for Dapagliflozin is 1.851% therefore, the HPLC method for the determination of Metformin Hydrochloride and Dapagliflozin is precise.

 


Specificity:

The Standard and sample solution were prepared as per the procedure and blank and excipient does not have any interference to the standard and sample chromatogram.

 

 

Figure No 6: Specificity Standard solution Chromatogram
 
Table No 5: Specificity Standard solution

RT [min]

Area

Height

Area %

Name

Tailing Factor

2.719

10933.64

2102.57

99.33

Metformin HCl

0.86191

5.664

73.50

9.91

0.67

Dapagliflozin

1.90933

 

Figure No 7: Specificity Sample solution chromatogram

 

Table No 6: Specificity Sample solutions

RT [min]

Area

Height

Area %

Name

Tailing Factor

2.725

10847.10

2056.13

99.31

Metformin HCL

0.88606

5.716

75.91

11.74

0.69

Dapagliflozin

1.12013

 

Robustness:

The method robustness was proven by purposefully altering the flow rate of the chromatography. Less than 2% was the average percentage RSD for determining the method robustness.

 

Table No.7: Data sheet for Robustness (Metformin Hydrochloride)

Change in parameter

 

Area of Slandered

Mean

SD

% RSD

 

Change in flow rate (±0.2ml/ min)

1.0ml/min

 

0.8ml/ min

14536.702

14551.808

42.28

 

0.290

14519.154

14599.57

1.2ml/ min

10113.191

10047.274

172.9

1.720

10177.533

9851.099

Table No.8: Data sheet for Robustness Dapagliflozin

Change in Parameter

Area of

Standard

Mean

SD

% RSD

Changes in Flow  rate

(± 0.2ml/min) 1.0ml/min

0.8ml/min

93.64

92.099

1.507

 

1.636

92.03

90.628

1.2ml/min

66.799

66.555

0.467

0.702

66.85

66.016

 
Stability of Analytical Solutions:

After the study of stability study it found that both Standard and sample solutions are stable for 24hrs at room temperature.

 

Table No.9: Data sheet for Stability of Analytical solutions (Metformin HCl)

S No
Name
Area
Assay
% Relative Change
% absolute Value
1
Standard solution-0 hrs
11217.58
NA
1.4789
NA
2
Standard solution -24 hrs
11383.48
NA
3
Standard solution-0 hrs
11162.54
100.58

NA

1.17

4
Standard solution -24 hrs
11292.07
101.75
 
Table No.10: Data sheet for Stability of Analytical solutions Dapagliflozin
Sr. No
Name
Area
Assay
% Relative Change
% absolute Value
1
Standard solution-0 hrs

76.486

NA

 

1.1309

 

 

NA

2
Standard solution -24 hrs

77.351

NA

3
Standard solution-0 hrs

78.226

97.25

 

 

  NA

 

0.34

4
Standard solution -24 hrs

78.5

97.59

 

Assay Analysis:

The % Assay of Metformin Hydrochloride and Dapagliflozin from the tablet was 99.11 % and 97.92 % respectively.

 

DISCUSSION:

RP-HPLC was used to analyze the formulation that contained Dapagliflozin and Metformin hydrochloride. The precision, accuracy, linearity, and range of these techniques serve as validation. These techniques produce precise and accurate outcomes. These approaches are less time consuming, steady, sensitive, robust, accurate, and exact because they require calculation on the part of the analyst. Accuracy, precision, specificity, robustness, linearity, and range are used to validate methods the findings of this procedure are precise and accurate. This method is less time-consuming, exact, and precise.

 

CONCLUSION:

With a correlation coefficient better than 0.99, the measured signal was demonstrated to be precise, accurate, and linear over the concentration range tested (30-70 ug/mL). Furthermore, a more economical and environmentally friendly chromatographic process is produced by the method. Metformin hydrochloride and Dapagliflozin had accuracy mean recovery values that are within the limit, at 101.88% and 99.35%, respectively. A precision RSD of no more than 2.0% is acceptable. It's found inside the range.
We conclude that the developed RP-HPLC validated method is robust, sensitive, affordable, accurate, and precise for the quantitative estimation of metformin hydrochloride and Dapagliflozin in formulation. It is also used for routine analysis of these drugs in the pharmaceutical industries.

 

ACKNOWLEDGMENT:

Smruthi Organics Limited, Solapur for providing API.

 

REFERENCE:

1.      Ravisankar P, Gowthami S, Rao GD. A review on analytical method development. Indian J Research in Pharmacy and Biotechnology. 2014; May 1; 2(3): 1183.

2.      Lavanya G, Sunil MM, Eswarudu MM. Analytical method validation: an updated review. International J Pharmaceutical Sciences and Research. 2013; Apr 1; 4(4): 1280.

3.      Tangri P, Rawat PS. Validation: A critical parameter for quality control of pharmaceuticals. Journal of Drug Delivery and Therapeutics. 2012; May 14; 2(3).

4.      Ajay S, Rohit S. Validation of analytical procedures: a comparison of ICH Vs Pharmacopoiea (USP) and FDA. Inter National Research J Pharmacy. 2012; 3(6): 39-42.

5.      Lambert J. Validation guidelines for pharmaceutical dosage forms. Health Canada. Health Products and Food Branch Inspectorate. 2004:7-15.

6.      Singh PS, Shah G. Analytical method development and validation. J Pharm Res. 2011; 4(5): 2330-2332.

7.      Ramamurthy M, Sarvanakumar K. Pharmaceutical validation. The Eastern Pharmacist. 1997; 476: 45-7.

8.      Agalloco J. Validation: an unconventional review and reinvention. PDA J Pharmaceutical Science and Technology. 1995; Jul 1; 49(4): 175-9.

9.      Pulla RP, Sastry BS, Prasad YR. Simultaneous Estimation of Metformin HCl and Sitagliptin Phosphate in Tablet Dosage Forms by RP-HPLC. Research J Pharma and Technology. 2011; 4(4): 646-9.

10.   Urooj A, Sundar PS, Vasanthi R,. Development and validation of RP-HPLC method for simultaneous estimation of Dapagliflozin and Metformin in bulk and in synthetic mixture. World J Pharm Pharm Sci. May 2017; 6(7): 2139-50.

11.   Deepan T, Rao MB, Dhanaraju MD. Development of validated stability indicating assay method for simultaneous estimation of Metformin and Dapagliflozin by RP-HPLC. European J Applied Sciences. Jan 2017; 9(4): 189-99.

12.   Bhavyasri K, Surekha T, Begum S. RP-HPLC Method for Dapagliflozin and Metformin HCL in Bulk and Combined Formulation. Arch Pharm Practice. 2021; 12(4-2021): 106-10.

13.   Dighe NS, Varade PR, Shinde GS,. Quantitative estimation and validation of Dapagliflozin and metformin hydrochloride in pharmaceutical dosage form by RP-HPLC. Asian J Rese in Chemistry. 2019; 12(3):136-42.

14.   Patel KJ, Chaudhary AB, Bhadani SM. Stability indicating RP-HPLC method development and validation for estimation of empagliflozin and metformin Hcl. World J Pharm Pharm Sci. Jul 2017; 6(9): 796-809.

15.   Debata J, Kumar S, Jha SK .New RP-HPLC method development and validation of Dapagliflozin in bulk and tablet dosage form. Int J Drug Dev Res. 2017; 9(2): 48-51.

16.   Dibyajyoti Saha. Design and Potential of Mass Spectrometry. Asian J. Pharm. Ana. 2011; 1(1): 1-2.

17.   G. Raveendra Babu, J. Srinivasa Rao, K. Suresh kumar, P. Jayachandra Reddy. Stability Indicating Liquid Chromatographic Method for Aripiprazole. Asian J. Pharm. Ana. 2011; 1(1): 3-7.

18.   N. Santhi Ch. Deepthi, S.S. Rajendran, S. Gananadhamu, G. Devala Rao, Sai Lohit. Spectrophotometric Estimation of Ziprasidone in Bulk and In Pharmaceutical Formulations. Asian J. Pharm. Ana. 2011; 1(1): 8-9.

19.   Akhilesh Gupta, Swati Rawat, Mayuri Gandhi, Jaydeep Singh Yadav. Method Development and Acid Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS. Asian J. Pharm. Ana. 2011; 1(1): 10-13.

20.   Akhilesh Gupta, Jaydeep Singh Yadav, Swati Rawat , Mayuri Gandhi. Method Development and Hydrolytic Degradation Study of Doxofylline by RP-HPLC and LC-MS/MS. Asian J. Pharm. Ana. 2011; 1(1): 14-18.

21.   Rajendran S.S., Santhi N., Kumar Nallasivan P., Sam Solomon W.D., Venkata Narayanan R.. Simultaneous Estimation of Cefixime and Ofloxacin in Bulk and Tablet Dosage Form. Asian J. Pharm. Ana. 2011; 1(2): 36-38.

22.   D. Sridharan, Umarani A. Thenmozhi, L. Pavan Kumar, Aswani Dutt Chintalapati, M. Venkata Ramanaiah, Yelika Phanikishore. Development and Validation of UV Spectrophotometric Method of Darifenacin Hydrobromide in Bulk and Tablet Dosage Form. Asian J. Pharm. Ana. 2011; 1(3): 43-45.

23.   J. Nagamallika, Aruna Mahesh. Development and Validation of Spectrophotometric Method for the Estimation of Aripiprazole in Tablet Dosage Form. Asian J. Pharm. Ana. 2011; 1(3): 46-49.

24.   Md. Ahsanul Haque, Mohammad Shahriar, Most. Nazma Parvin, S. M. Ashraful Islam. Validated RP-HPLC Method for Estimation of Ranitidine Hydrochloride, Domperidone and Naproxen in Solid Dosage Form. Asian J. Pharm. Ana. 1(3): 59-63.

25.   Rawat S, Gupta A. Spectrophotometric Method for Simultaneous Estimation of Nimesulide and Diclofenac Sodium in Pharmaceutical Dosage Forms. Asian J. Pharm. 2011; 1(4): 85-87.

 

 

 

Received on 25.07.2024      Revised on 22.11.2024

Accepted on 03.01.2025      Published on 01.07.2025

Available online from July 05, 2025

Research J. Pharmacy and Technology. 2025;18(7):3273-3277.

DOI: 10.52711/0974-360X.2025.00472

© RJPT All right reserved

 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.